Michael J. Gallagher, Peter A. McCullough. The role of B-type natriuretic peptide in the diagnosis and treatment of decompensated heart failure[J]. Journal of Geriatric Cardiology, 2004, 1(1): 21-28.
Citation: Michael J. Gallagher, Peter A. McCullough. The role of B-type natriuretic peptide in the diagnosis and treatment of decompensated heart failure[J]. Journal of Geriatric Cardiology, 2004, 1(1): 21-28.

The role of B-type natriuretic peptide in the diagnosis and treatment of decompensated heart failure

  • Heart failure (HF) is a common disease associated with increasing age. B-type natriuretic peptide (BNP), is a cardiac neurohormone, and is released as prepro BNP and then enzymatically cleaved to the N-terminal-proBNP (NT-proBNP) and BNP upon ventricular myocyte stretch. Blood measurements of BNP have been used to identify patients with HF. The BNP assay is currently used as a diagnostic and prognostic aid in HF. In general, a BNP level below 100 pg/mL excludes acutely decompensated HF and levels > 500 pg/ml indicate decompensation. Recombinant human BNP (hBNP, nesiritide) is an approved intravenous treatment for acute, decompensated HF. Nesiritide given in supraphysiologic doses causes vasodilation, natriuresis, diuresis, and improved symptoms over the course of a 48-hour infusion. This paper will sort out the literature concerning the use of this peptide both as a diagnostic test and as an intravenous therapy.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return